The company’s recent finding that in mouse models low doses of both ZKPr1 and ZKPr2 specifically and greatly reduce excess visceral fat at commercially attainable and profitable doses, coupled with their nontoxicity and stability in the circulation (10 days for ZKPr1 and 3-4 days for ZKPr2), make them well qualified to become successful drugs for human applications to treat excess visceral fat in both non-obese and obese subjects, via either systemic or oral administration methods, with the potential treatments including:

• Treatment of normal weight subjects of any age with excess visceral fat.
• Co-treatment of obese subjects of any age treated with obesity drugs resulting both in proportionally much greater loss of excess visceral fat, compared to subcutaneous fat, and simultaneous improvement of associated health disorders (diabetes, hypertriglyceridemia, survival) as they have already been proven by our research.

Availability of the Proteins: Both ZKPr1 and ZKPr2 are commercially available in either recombinant or highly purified forms.

Significance For Health

Weight reducing drugs result in a maximum of 25% weight loss and a similar decrease in visceral fat. Adding non-toxic ZKPr1, either orally or via injection as an add-on treatment would be expected to ensure a proportionally much greater (~90%) reduction of visceral fat resulting in numerous additional health benefits.

A growing population of people, particularly among the elderly, who have excess visceral fat with serious health consequences but are otherwise normal-weight or slightly overweight and are not candidates for using weight loss drugs, can also greatly benefit from the use ofZKPr1.

Significance For Drug Companies

Considering serious competition among the producers of weight loss drugs, developing yet another drug for specific reduction of visceral fat, a first in the kind, would be expected to significantly increase the value of the owner of that technology.